Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC) is a head and neck tumor. Studies have shown that more than 70% of patients are diagnosed with locally advanced nasopharyngeal carcinoma at the time of initial diagnosis. The 3-year survival rate of locally advanced nasopharyngeal carcinoma after chemotherapy is over 90%, but 30% of patients still have recurrence and distant metastasis. Therefore, while improving the level of radiation therapy technology, we should study multidisciplinary comprehensive treatment methods and put forward the biological concept of "cure". Induction chemotherapy can effectively creat

Trial Details

NCT ID

NCT05508347

Phase

PHASE2

Sponsor

Sichuan Cancer Hospital and Research Institute

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

• Nituzumab/placebo

Locations (sample)

• Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

• Voluntarily participate and sign the informed consent in writing.
• Age: 18-70 years old, gender is not limited.
• Nasopharynx squamous cell carcinoma diagnosed by histopathology.
• Nasopharyngeal carcinoma 2018 AJCC (Eighth Edition) staging: t2-4n2m0 (metastatic lymph nodes have one of the following risk factors: the shortest …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →